Risk factors
Atara Biotherapeutics (ATRA) risk factors
Item 1A of every Atara Biotherapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks8 new12 dropped22 reworded
Severe cash shortage with only $8.5 million remaining as of December 31, 2025, threatening operations. Reliance on single approved product Ebvallo and partner Pierre Fabre for commercialization. Ongoing executive departures and staff reductions straining internal financial controls.
Filed Mar 16, 2026 - FY2024 10-K risk factors84 risks
The company relies heavily on a single approved product, partnerships, and additional capital to survive ongoing losses and workforce reductions.
Filed Mar 07, 2025